RESUMEN
Fish oil, which is rich in eicosapentaenoic acid (EPA), has been found to have immunomodulatory effects. We examined whether administration of purified EPA affected survival of fully mismatched murine cardiac allografts. Hearts from C57BL/10 (H-2(b)) mice were transplanted into CBA (H-2(k)) recipients treated with one intraperitoneal dose of purified EPA the day of transplantation. Untreated CBA recipients and recipients given 0.1 g/kg of EPA rejected C57BL/10 hearts (median survival time [MST], 8 and 13 days, respectively). With a 1.0 g/kg dose of EPA, graft survival was markedly prolonged (MST >100 days). To determine whether regulatory cells were generated, naïve mice (secondary recipients) underwent adoptive transfer of splenocytes from EPA-treated primary recipients and cardiac allograft transplantation. Adoptive transfer of whole, CD4(+) and CD4(+)CD25(+) splenocytes from EPA-treated recipients induced indefinite survival in secondary recipients. Flow cytometry showed that the CD4(+)CD25(+) cells were Foxp3(+). In reverse transcriptase-polymerase chain reaction (RT-PCR) studies, the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA was upregulated by EPA treatment. A PPARgamma antagonist abrogated the prolongation of graft survival induced by EPA treatment (MST, 13 days). Thus, in our model, purified EPA induced prolonged survival of fully mismatched cardiac allografts and generated regulatory T cells dependent on PPARgamma activation.
Asunto(s)
Ácido Eicosapentaenoico/farmacología , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Corazón/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Traslado Adoptivo , Animales , Compuestos de Bencidrilo , Ácido Eicosapentaenoico/administración & dosificación , Compuestos Epoxi/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos CBA , PPAR gamma/antagonistas & inhibidores , PPAR gamma/biosíntesisRESUMEN
A strategy for producing high-level hematopoietic chimerism after non-myeloablative conditioning has been established in the rhesus macaque. This strategy relies on hematopoietic stem cell transplantation after induction with a non-myeloablative dose of busulfan and blockade of the IL2-receptor in the setting of mTOR inhibition with sirolimus and combined CD28/CD154 costimulation blockade. Hematopoietic stem cells derived from bone marrow and leukopheresis products both were found to be successful in inducing high-level chimerism. Mean peripheral blood peak donor chimerism was 81% with a median chimerism duration of 145 days. Additional immune modulation strategies, such as pre-transplant CD8 depletion, donor-specific transfusion, recipient thymectomy or peritransplant deoxyspergualin treatment did not improve the level or durability of chimerism. Recipient immunologic assessment suggested that chimerism occurred amidst donor-specific down-regulation of alloreactive T cells, and the reappearance of vigorous T-mediated alloreactivity accompanied rejection of the transplants. Furthermore, viral reactivation constituted a significant transplant-related toxicity and may have negatively impacted the ability to achieve indefinite survival of transplanted stem cells. Nevertheless, this chimerism-induction regimen induced amongst the longest-lived stem cell chimerism reported to date for non-human primates and thus represents a platform upon which to evaluate emerging tolerance-induction strategies.
Asunto(s)
Quimerismo , Trasplante de Células Madre Hematopoyéticas/métodos , Terapia de Inmunosupresión/métodos , Macaca mulatta/inmunología , Animales , Trasplante de Médula Ósea/métodos , Busulfano/farmacología , Infecciones por Citomegalovirus/complicaciones , Inmunosupresores/farmacología , Leucaféresis/métodos , Macaca mulatta/genética , Receptores de Interleucina-2/antagonistas & inhibidores , Sirolimus/farmacología , Linfocitos T/inmunología , Tolerancia al TrasplanteRESUMEN
BACKGROUND: We previously reported that intratracheal delivery of alloantigen induced regulatory cells in a mouse heart transplantation model. We investigated the roles of costimulatory pathways in the induction of regulatory cells by intratracheal delivery of alloantigen. METHODS: CBA (H-2k) mice were pretreated with intratracheal delivery of splenocytes (1 x 10(7)) from C57BL/10 (H-2b) mice and administration of monoclonal antibodies (mAb) specific for programmed death (PD)-1 and its ligands, programmed death-ligand (PD-L)1 and PD-L2, CD70, CD134 ligand (CD134L), CD153, CD137L, or receptor activator of nuclear factor-kappaB (NF-kappaB) (RANK). Seven days later, naive CBA mice underwent adoptive transfer of splenocytes (5 x 10(7)) from the pretreated CBA mice and transplantation of C57BL/10 heart. RESULTS: Adoptive transfer of splenocytes from CBA mice that had been pretreated with intratracheal delivery of C57BL/10 splenocytes significantly prolonged the survival of C57BL/10 allograft (median survival time [MST], 68 days) as compared with adoptive transfer from untreated CBA mice (MST, 12 days). Concomitant administration of control immunoglobulin (Ig)G, anti-PD-L2 mAb, or anti-CD137L along with intratracheal delivery did not significantly affect the prolongation (MST, 72, 68, and 65 days, respectively). In contrast, anti-PD-1, anti-PD-L1, anti-CD70, anti-CD134L, anti-CD153, or anti-RANK mAb abrogated the prolongation induced by adoptive transfer from the pretreated mice with intratracheal delivery (MST, 18, 17, 16, 14, 10, and 18 days, respectively). CONCLUSION: The PD-1/PD-L1, CD27/CD70, CD134/CD134L, CD30/CD153, and tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE)/RANK interactions are independently required for generation of regulatory cells by intratracheal delivery of alloantigen.
Asunto(s)
Supervivencia de Injerto/fisiología , Isoantígenos/administración & dosificación , Transfusión de Linfocitos/métodos , Traslado Adoptivo , Animales , Intubación Intratraqueal , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Modelos Animales , Trasplante Homólogo/inmunologíaRESUMEN
We reported stable mixed chimerism and specific tolerance to a fully allogeneic graft after a minimally myelosuppressive regimen including costimulation blockade (CB), donor bone marrow cells (BMC), and busulfan (Bu), a chemotherapeutic conditioning agent that makes niches for engraftment of BMC. For clinical application, the strategy may have the limitation of the number of donor BMC when a deceased donor offers transplants to multiple recipients. Herein, we examined whether donor splenocytes can serve as an alternative source to induce mixed chimerism and tolerance. When a C57BL/6 (H-2b) recipient was treated with CB (CTLA4-Ig and anti-CD154 mAb, on days 0, 2, 4, 6) and donor BALB/c (H-2d) BMC (2 x 10(7) cells on day 0) in the absence of Bu, survival of BALB/c skin graft was remarkably prolonged but not indefinite (median survival time [MST]: 138 days). The recipients never showed durable chimerism. When the recipient was treated with CB and donor splenocytes ([DST] 2 x 10(7) cells on day 0), survival was not indefinite either (MST: 114 days). When the dose of DST was increased to 2 x 10(8) cells, survival was further prolonged; two of six recipients had indefinite survival (MST: 132 days). Moreover, one recipient showed a low level of chimerism. When treated with CB, donor DST (2 x 10(7) cells on day 0) and Bu (20 mg/kg, day -1), six of seven recipients showed a stable, high level of chimerism and enjoyed tolerance of skin allografts. DST combined with CB and Bu may be an alternative source of hematopoietic stem cells to induce mixed chimerism and transplantation tolerance in our model.
Asunto(s)
Transfusión de Linfocitos , Trasplante de Piel/inmunología , Animales , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Modelos Animales , Trasplante de Células Madre , Quimera por Trasplante , Trasplante HomólogoRESUMEN
INTRODUCTION: A virally induced alloreactive memory seems to represent a potent barrier to tolerance induction but the combination of 15-deoxyspergualin (DSG), an inhibitor of NFkB translocation, with costimulation blockade (CB)-based chimerism as an induction regimen can overcome a preformed anti-donor memory response. In this study, we investigate the ability of DSG with CB to inhibit a naive alloimmune responses. METHODS: A BALB/c (H-2d) skin or heart was transplanted into a C57BL/6 (H-2b) recipient treated with anti-CD154 mAb (MR1; 500 mcg/d on days 0, 2, 4, 6) alone, DSG (5 mg/kg/d, days 0 to 7) alone, or both agents. Proliferation of alloreactive T cells after each treatment was also examined using a graft-versus-host disease (GvHD) model using the fluorescent dye CFSE. RESULTS: Treatment with DSG alone induced prolonged survival of the cardiac allografts (median survival time [MST]: 97.5 days). MR1 alone induced indefinite survival of cardiac allografts, although at 150 days after transplantation, the histology showed changes characteristic of chronic rejection, including interstitial fibrosis, infiltration of mononuclear cells, and intimal hyperplasia in coronary vessels. Combined treatment with DSG and MR1 induced donor-specific unresponsiveness in all recipients, graft histology showed only minimal infiltration. Treatment with DSG and MR1 also significantly prolonged the survival of skin allografts (MST: 31 days) compared with that of DSG or MR1 alone (MST: 17 and 14 days, respectively). In the GvHD model assessed with CFSE, the combined treatment was the more effective to suppress proliferation of alloreactive T cells while DSG alone inhibited proliferation more than MR1 alone. CONCLUSION: DSG potentiates anti-CD154 therapy to suppress the alloimmune response.
Asunto(s)
Guanidinas/farmacología , Trasplante de Corazón/inmunología , Isoanticuerpos/inmunología , Trasplante de Piel/inmunología , Animales , Formación de Anticuerpos/efectos de los fármacos , Supervivencia de Injerto/inmunología , Memoria Inmunológica , Inmunosupresores/farmacología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Trasplante Homólogo/inmunologíaAsunto(s)
Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Fragmentos de Péptidos/uso terapéutico , Animales , Terapia de Inmunosupresión/métodos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Fragmentos de Péptidos/administración & dosificación , Tráquea , Trasplante HomólogoAsunto(s)
Inhibidores de la Ciclooxigenasa/farmacología , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Corazón/inmunología , Tolerancia Inmunológica/efectos de los fármacos , Nitrobencenos/farmacología , Sulfonamidas/farmacología , Animales , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Isoenzimas/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Prostaglandina-Endoperóxido Sintasas/metabolismo , Trasplante HomólogoAsunto(s)
Antitrombina III/farmacología , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Corazón/inmunología , Animales , Antitrombina III/administración & dosificación , Supervivencia Celular/efectos de los fármacos , Citocinas/biosíntesis , Inyecciones Intravenosas , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Factores de Tiempo , Trasplante HomólogoAsunto(s)
Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Isoantígenos/farmacología , Receptores de Interleucina-2/inmunología , Traslado Adoptivo , Animales , Supervivencia de Injerto/efectos de los fármacos , Intubación Intratraqueal , Isoantígenos/administración & dosificación , Transfusión de Linfocitos , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Bazo/inmunología , Trasplante HomólogoAsunto(s)
Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Isoantígenos/farmacología , Transfusión de Linfocitos/métodos , Tacrolimus/farmacología , Animales , Inmunosupresores/farmacología , Intubación Intratraqueal , Isoantígenos/administración & dosificación , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Bazo/inmunología , Factores de TiempoRESUMEN
BACKGROUND: Dendritic cells can mount immune response as competent antigen presenting cells. Recently, it has been reported that immature dendritic cells induce prolongation of allograft survival. However, the ability of mature dendritic cells to induce operational tolerance is unclear. Therefore, in this study, we examined the ability of splenic mature dendritic cells to induce operational tolerance to fully allogeneic antigens using mouse heterotopic heart transplantation model. METHODS: CBA (H2k) mice received i.v. injections with donor splenic dendritic cells or B cells in the absence or presence of monoclonal antibody (mAb) specific for CD40 ligand or CD80/CD86 2 weeks before transplantation of a C57BL/10 (H2b) heart. RESULTS: When donor dendritic cells were injected i.v. 2 weeks before transplantation, rejection response was accelerated compared with that of naive mice [median survival time (MST) = 7 and 8 days, respectively]. However, when CD40 pathway was blocked by anti-CD40 ligand mAb, i.v. injection of donor dendritic cells but not B cells induced indefinite graft survival (MST >100 and 20 days, respectively). Mice treated with anti-CD40 ligand mAb alone rejected their grafts with a MST of 18 days. Intravenous injection of donor dendritic cells and B cells in combination with anti-CD80/CD86 mAbs was less effective to induce graft prolongation (MST = 9.5 and 13 days, respectively). CONCLUSIONS: Therefore, under blockade of CD40 pathway, mature dendritic cells were tolerogens in vivo independent of CD80/86 pathways.
Asunto(s)
Antígenos CD40/inmunología , Ligando de CD40/inmunología , Células Dendríticas/inmunología , Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Terapia de Inmunosupresión/métodos , Traslado Adoptivo , Animales , Anticuerpos Monoclonales/farmacología , Citotoxicidad Inmunológica , Prueba de Cultivo Mixto de Linfocitos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Modelos Animales , Bazo/inmunología , Factores de Tiempo , Donantes de Tejidos , Trasplante Homólogo/inmunologíaRESUMEN
Simultaneous blockade of the CD28 and CD40 T cell costimulatory pathways has been shown to effectively promote skin allograft survival in mice. Furthermore, blockade of one or both of these pathways has played a central role in the development of strategies to induce mixed hematopoietic chimerism and allospecific tolerance. It has recently been observed that the beneficial effects of CD40 blockade and donor splenocytes in prolonging skin graft survival can be abrogated by some viral infections, including lymphocytic choriomeningitis virus (LCMV). In this study, we show that LCMV infection prevents prolonged allograft survival following CD28/CD40 combined blockade. We further show that LCMV prevents the induction of allospecific tolerance and mixed hematopoietic chimerism, while delay of infection for 3-4 wk posttransplant has no effect on tolerance induction. Because of reports of anti-H-2(d) activity following LCMV infection, we assayed the ability of LCMV-specific T cells to respond to alloantigen at a single cell level. Although we confirm that LCMV infection induces the generation of alloreactive cells, we also demonstrate that LCMV-specific T cells do not divide in response to alloantigen. The alloresponse suppressed by costimulation blockade is restored by LCMV infection and correlates with increased dendritic cell maturation. We hypothesize that the costimulation blockade-resistant rejection mediated by LCMV could be partly attributable to the up-regulation of alternative costimulatory pathways subsequent to LCMV-induced dendritic cell maturation.
Asunto(s)
Tolerancia Inmunológica , Isoantígenos/inmunología , Coriomeningitis Linfocítica/inmunología , Quimera por Trasplante , Animales , Trasplante de Médula Ósea , Antígenos CD28/fisiología , Antígenos CD40/fisiología , Células Dendríticas/fisiología , Supervivencia de Injerto , Interferón gamma/biosíntesis , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Linfocitos T/inmunología , Trasplante HomólogoAsunto(s)
Antígenos CD4/inmunología , Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Isoantígenos/administración & dosificación , Bazo/inmunología , Tolerancia al Trasplante/inmunología , Trasplante Homólogo/inmunología , Administración Oral , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Isoantígenos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBARESUMEN
BACKGROUND: The effectiveness of donor-specific blood transfusion (DST) before transplantation has been established. Anti-CD4 monoclonal antibody (anti-CD4) augments the ability of DST to induce indefinite prolongation. Therefore, we investigated the importance of thymus to maintain the unresponsiveness to alloantigens. METHODS: CBA mice were pretreated with 0.25 mL of DST or two doses of anti-CD4 before transplantation of a C57BL/10 heart. Some mice were thymectomized. RESULTS: Naive CBA mice rejected C57BL/10 grafts acutely with a median survival time of 7 days. When mice were pretreated with anti-CD4 plus DST 4 weeks before transplantation, all grafts survived indefinitely (>100 days), whereas mice treated with DST alone or anti-CD4 alone rejected acutely (median survival time, 7 and 12 days, respectively). To investigate the importance of thymus, mice pretreated with anti-CD4 plus DST 4 weeks before transplantation were thymectomized or underwent a sham operation 1 day before grafting. Mice with the sham operation accepted grafts indefinitely, whereas thymectomized mice rejected the majority of the grafts (median survival time, 20 days). CONCLUSIONS: The thymus is important in maintaining the operational tolerance induced by anti-CD4 plus DST 4 weeks before grafting.
Asunto(s)
Trasplante de Corazón/inmunología , Timo/inmunología , Tolerancia al Trasplante , Traslado Adoptivo , Animales , Anticuerpos Monoclonales/administración & dosificación , Antígenos de Grupos Sanguíneos/inmunología , Transfusión Sanguínea , Antígenos CD4/inmunología , Citometría de Flujo , Rechazo de Injerto/inmunología , Supervivencia de Injerto/inmunología , Isoantígenos/inmunología , Linfocitos/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , TimectomíaRESUMEN
Mixed hemopoietic chimerism has the potential to correct genetic hemological diseases (sickle cell anemia, thalassemia) and eliminate chronic immunosuppressive therapy following organ transplantation. To date, most strategies require either recipient conditioning (gamma-irradiation, depletion of the peripheral immune system) or administration of "mega" doses of bone marrow to facilitate reliable engraftment. Although encouraging, many issues remain that may restrict or prevent clinical application of such strategies. We describe an alternative, nonirradiation based strategy using a single dose of busulfan, costimulation blockade, and T cell-depleted donor bone marrow, which promotes titratable macrochimerism and a reshaping of the T cell repertoire. Chimeras exhibit robust donor-specific tolerance, evidenced by acceptance of fully allogeneic skin grafts and failure to generate donor-specific proliferative responses in an in vivo graft-versus-host disease model of alloreactivity. In this model, donor cell infusion and costimulation blockade without busulfan were insufficient for tolerance induction as donor-specific IFN-gamma-producing T cells re-emerged and skin grafts were rejected at approximately 100 days. When applied to a murine beta-thalassemia model, this approach allows for the normalization of hemologic parameters and replacement of the diseased red cell compartment. Such a protocol may allow for clinical application of mixed chimerism strategies in patients with end-stage organ disease or hemoglobinopathies.
Asunto(s)
Anticuerpos Bloqueadores/administración & dosificación , Trasplante de Médula Ósea/inmunología , Busulfano/administración & dosificación , Hemoglobinopatías/genética , Hemoglobinopatías/terapia , Terapia de Inmunosupresión , Activación de Linfocitos/inmunología , Tolerancia al Trasplante/inmunología , Animales , Antígeno B7-1/inmunología , Antígenos CD28 , Linfocitos T CD4-Positivos , Antígenos CD40/inmunología , Ligando de CD40/inmunología , Línea Celular , Supresión Clonal/efectos de los fármacos , Supresión Clonal/genética , Citotoxicidad Inmunológica/efectos de los fármacos , Citotoxicidad Inmunológica/genética , Hemoglobinopatías/inmunología , Terapia de Inmunosupresión/efectos adversos , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Ratones SCID , Quimera por Radiación/inmunología , Linfocitos T Citotóxicos/efectos de los fármacos , Linfocitos T Citotóxicos/inmunología , Volumetría , Tolerancia al Trasplante/efectos de los fármacos , Tolerancia al Trasplante/genéticaRESUMEN
BACKGROUND: Soluble protein delivered through the mucosal surface can induce immunological unresponsiveness. The purpose of this study was to determine if prior exposure to alloantigen via the trachea could modulate the immune response to subsequent cardiac allografts. METHODS: Hearts from C57BL/10(H2b) mice were transplanted into CBA(H2k) recipients. Recipient mice were given donor 1x10(7) splenocytes into the trachea with or without antibody specific for mouse CD80 (1G10) and/or CD86 (GL1) (100 microg each) 7 days before transplantation. RESULTS: All grafts survived in recipients treated with intratracheal delivery of alloantigen for over 35 days (mean survival time [MST], 56 days), whereas naive control mice and mice treated with syngeneic antigen rejected grafts acutely (MST, 8 and 7 days, respectively). Interestingly, when 1G10, GL1, or both of them were combined with the protocol, the majority of grafts were rejected within 21 days after grafting (MST, 7, 15, and 17 days, respectively). CONCLUSION: Intratracheal delivery of alloantigen induced significantly prolonged survival of fully mismatched cardiac allografts and the effect was abrogated by the blockade CD80 and/or CD86 pathway.
Asunto(s)
Trasplante de Corazón/inmunología , Isoantígenos/administración & dosificación , Animales , Formación de Anticuerpos/inmunología , Supervivencia de Injerto/inmunología , Intubación Intratraqueal , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBAAsunto(s)
Trasplante de Corazón/inmunología , Tolerancia al Trasplante/inmunología , Traslado Adoptivo/métodos , Animales , Linfocitos B/trasplante , Linfocitos T CD4-Positivos/trasplante , Linfocitos T CD8-positivos/trasplante , Células Dendríticas/trasplante , Rechazo de Injerto/inmunología , Inmunidad Mucosa , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Trasplante Homólogo , Trasplante IsogénicoAsunto(s)
Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Tolerancia al Trasplante , Administración Oral , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/inmunología , Trasplante de Células/métodos , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Bazo/citologíaRESUMEN
Oral administration can induce unresponsiveness to protein antigens. Therefore, we examined whether oral administration of xeno-antigen could induce the prolonged survival of xenogeneic skin grafts. CBA mice were given 1 x 10(7) SD rat splenocytes orally, 7 days before transplantation of a SD rat skin in the presence or absence of a non-depleting anti-CD4 monoclonal antibody (mAb) (YTS177, 200 microg/dose, 8 and 7 days relative to transplantation). All skin grafts survived with a median survival time (MST) of 62 days when xeno-antigens were administered orally in combination with anti-CD4 mAb. Mice treated with anti-CD4 mAb alone or oral administration of xeno-antigen alone induced modest prolonged survival of rat skin grafts (MST = 18 and 19 days, respectively) while naive mice rejected rat skin acutely (MST= 12 days). Oral administration alone or combined with anti-CD4 mAb reduced the level of xeno-antibody production compared with that in untreated mice after transplantation. Xenogeneic mixed leukocyte response was reduced when splenocytes from mice pre-treated with oral administration of xenogeneic cells were used as the responder compared with that in untreated mice. Oral delivery of xeno-antigen plus non-depleting anti-CD4 mAb can induce prolongation of concordant xenogeneic skin grafts.